Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161...

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU...

OSAKA, Japan — Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the...

DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial...

AUCKLAND, New Zealand, June 24, 2024. Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that results from...

Researchers conducted a randomized controlled trial to determine the clinical efficacy and cost-efficiency of the WalkBack personalized, walking, and...

These non-invasive, non-pharmacological techniques encompass meditation-based modalities that offer profound benefits increasingly validated by modern...

LUND, Sweden, June 25, 2024. Camurus today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized,...

South San Francisco, CA -- July 3, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III...

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...